AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-107 (cancelled).

108 (new). A mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959.

109 (new). An antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-2960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof.

110 (new). The antibody of claim 109 which is a $F(ab')_2$ fragment.

111 (new). The antibody of claim 109 which is a F(ab') fragment.

112 (new). The antibody of claim 109 which is conjugated to a therapeutic agent.

113 (new). The antibody of claim 112, wherein the therapeutic agent is a cytotoxin.

114 (new). The antibody of claim 113 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.

115 (new). The antibody of claim 109 comprising at least one modification in the Fc region.

116 (new). An isolated antibody that competes for binding to FcγRIIB with the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959 as determined by ELISA.

117 (new). The antibody of claim 116 which is a $F(ab')_2$ fragment.

118 (new). The antibody of claim 116 which is a F(ab) fragment.

119 (new). The antibody of claim 116 which is conjugated to a therapeutic agent.

120 (new). The antibody of claim 119, wherein the therapeutic agent is a cytotoxin.

121 (new). The antibody of claim 120 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.

122 (new). The antibody of claim 116 comprising at least one modification in the Fc region.

123 (new). A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.

124 (new). A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody that competes for binding to FcγRIIB with the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959 as determined by ELISA; and (ii) a pharmaceutically acceptable carrier.

125 (new-withdrawn). A method of treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no PTA-5962, clone 2D11 having ATCC accession no. PTA-2960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen binding fragment thereof.

126 (new-withdrawn). The method of claim 125, wherein said IgE-mediated allergic disorder is asthma, allergic rhinitis, gastro-intestinal allergies, eosinophilia, conjunctivitis, or glomerular.

127 (new-withdrawn). The method of claim 125, wherein said patient is human.

128 (new-withdrawn). The method of claim 125, wherein said antibody is humanized.

129 (new-withdrawn). The method of claim 125, wherein the antibody is a $F(ab')_2$ fragment.

130 (new withdrawn). The method of claim 125, wherein the antibody is a F(ab′) fragment.